A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to stronger immune responses and longer survival.
These findings from a large study led by the University of Helsinki highlight how certain ovarian cancer cells can shape the immune response around them, offering clues that may help refine prognosis and future therapies.
By closely examining ovarian cancer tissue from more than 280 women, researchers discovered that patients tended to do better when immune cells gathered in groups at the edge of the tumor, where cancer meets healthy tissue. This border area turned out to be a crucial place where the body’s defence tries to stop the disease from spreading.
The…